Mineralys Therapeutics (MLYS) 2026 meeting approves directors and auditor
Mineralys Therapeutics, Inc. (MLYS) held its 2026 annual meeting on May 21, 2026, where shareholders approved two key proposals. They elected three Class III directors to three-year terms and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Both proposals passed with the necessary affirmative votes from common stockholders.
Mineralys CMO David Rodman sells $11,488 in shares
David Rodman, Chief Medical Officer of Mineralys Therapeutics (NASDAQ:MLYS), sold 417 shares of company stock for $11,488 on May 18, 2026, after acquiring them through stock option exercise. This transaction occurred via a Rule 10b5-1 trading plan. The company's stock has seen recent volatility but provided a 70% return over the past year, with analysts holding a "Strong Buy" rating despite potential overvaluation.
Mineralys CMO David Rodman sells $11,488 in shares
Mineralys Therapeutics CMO David Rodman sold 417 shares of company stock for $11,488 after acquiring them through exercised stock options. This sale was conducted under a Rule 10b5-1 trading plan. The transaction occurs as Mineralys shares have seen a 70% return over the past year, despite recent volatility, and the company has received a "Strong Buy" consensus rating from analysts, though InvestingPro suggests it may be slightly overvalued.
Mineralys (NASDAQ: MLYS) CMO exercises options and sells 417 pre-planned shares
Mineralys Therapeutics, Inc.'s Chief Medical Officer, David Malcom, reported a pre-planned stock transaction. He exercised stock options for 417 shares at $15.44 each and simultaneously sold those 417 common shares at $27.55 each under a Rule 10b5-1 trading plan. Following these transactions, Malcom directly holds 63,443 common shares and 4,167 stock options, indicating this activity impacted only a minor portion of his total holdings.
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics will present new data from its Phase 3 Launch-HTN trial of lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The oral presentation will highlight the efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease (CKD). Lorundrostat is an aldosterone synthase inhibitor being developed to address hypertension and related comorbidities driven by dysregulated aldosterone.
417‑share proposed sale by Mineralys (NASDAQ: MLYS) via cashless exercise
Mineralys Therapeutics (NASDAQ: MLYS) has filed a Form 144, indicating a proposed sale of 417 shares of common stock on May 18, 2026. This sale stems from the exercise of employee stock options and will be executed through a broker-assisted cashless exercise. The filing also notes multiple recent dispositions by David Rodman between February and May 2026, with a proposed value of $11,488.35 for the current 417-share sale.
Lorundrostat Phase 3 data in uncontrolled blood pressure, CKD going to ESH 2026
Mineralys Therapeutics (Nasdaq: MLYS) announced it will present new Phase 3 data from its Launch-HTN trial for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The data, focusing on patients with uncontrolled hypertension and chronic kidney disease (CKD), will be presented orally on May 30, 2026, by Liffert Vogt, MD, PhD. The trial evaluated lorundrostat's efficacy and safety in adults whose blood pressure remained uncontrolled despite existing antihypertensive medications, with the primary endpoint being the change from baseline in systolic BP at six weeks.
Mineralys Therapeutics Announces Presentation of New Data
Mineralys Therapeutics (Nasdaq: MLYS) announced new data from its Phase 3 Launch-HTN trial for lorundrostat, targeting hypertension and chronic kidney disease (CKD), will be presented at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) on May 30, 2026. The oral presentation will highlight the efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and CKD. Lorundrostat is an aldosterone synthase inhibitor designed to reduce blood pressure and manage related comorbidities by addressing dysregulated aldosterone levels, a key driver in these conditions.
Mineralys Therapeutics (Nasdaq: MLYS) Grants Equity Awards to New Hires
Mineralys Therapeutics (Nasdaq: MLYS) has awarded stock options and restricted stock units to two new non-executive employees as a hiring incentive. These awards, totaling 29,760 stock option shares and 22,320 restricted stock units, were granted under the company's 2025 Employment Inducement Incentive Award Plan and vest over four years. The grants comply with Nasdaq Listing Rule 5635(c)(4), allowing equity awards to attract new talent outside of shareholder-approved plans.
Trading the Move, Not the Narrative: (MLYS) Edition
This article provides an in-depth stock analysis for Mineralys Therapeutics Inc. (MLYS) focusing on predictive AI-generated trading strategies. It highlights a significant 152.7:1 risk-reward setup, targeting a 43.0% gain, and outlines specific position, momentum, and risk-hedging strategies for various timeframes. The analysis suggests weak near-term sentiment but strong mid and long-term potential.
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Vanguard Group Inc.
Vanguard Group Inc. increased its stake in Mineralys Therapeutics (MLYS) by 11.1% in the fourth quarter, owning 3.35 million shares. Insider activity for the company was mixed, with significant purchases by RA Capital Management and sales by director Daphne Karydas. Analysts broadly maintain a "Moderate Buy" rating for MLYS, with an average price target of $49.14, following the company's recent report of a smaller-than-expected quarterly loss.
Mineralys Therapeutics Insider Sold Shares Worth $652,638, According to a Recent SEC Filing
This article reports on a recent SEC filing indicating that an insider at Mineralys Therapeutics sold shares valued at $652,638. The sale details and the identity of the insider are expected to be further elaborated in the complete SEC filing.
David Malcom Rodman Sells 2,171 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
David Malcom Rodman, an insider at Mineralys Therapeutics (NASDAQ:MLYS), sold 2,171 shares of the company's stock for approximately $64,500.41 on May 11th, reducing his stake by 3.02%. This transaction was part of a pre-arranged Rule 10b5-1 trading plan, with further sales occurring throughout May, April, March, and February. The company recently reported a narrower-than-expected quarterly loss of ($0.47) per share, and analysts currently rate the stock as a "Moderate Buy" with an average target price of $49.14 despite the insider selling.
Mineralys (NASDAQ: MLYS) CMO exercises options, sells 22,575 shares in 10b5-1 plan
Mineralys Therapeutics (NASDAQ: MLYS) Chief Medical Officer, David Malcom Rodman, sold a total of 22,575 shares of company stock between May 11-13, 2026, at weighted-average prices around the high-$20s per share. Concurrently, he exercised stock options for 16,226 shares at strike prices ranging from $1.08 to $16.00. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025, and after the sales, Rodman directly holds 63,443 shares.
Mineralys CMO Rodman sells $652,637 in company stock
David Malcom Rodman, CMO of Mineralys Therapeutics, sold 22,575 shares of company stock for approximately $652,637 between May 11 and May 13, 2026, while also acquiring 16,226 shares through option exercises. These transactions were conducted under a Rule 10b5-1 trading plan. The company recently reported strong Q1 2026 earnings, surpassing analyst expectations, and announced the acceptance of its New Drug Application for lorundrostat.
Multiple affiliate sales and option exercises at Mineralys Therapeutics (MLYS)
Mineralys Therapeutics, Inc. (MLYS) filed a Form 144 detailing multiple affiliate stock sales and option exercises. The filing shows various dispositions of common stock by David Rodman between February 9, 2026, and May 12, 2026, through both broker-assisted and cash transactions, along with an exercise-related transfer on May 13, 2026. The report includes key figures such as shares outstanding and specific details of sales and employee stock option exercises.
[144] Mineralys Therapeutics, Inc. SEC Filing
Mineralys Therapeutics (NASDAQ: MLYS) has filed a Form 144, indicating a proposed sale of 6,348 shares of common stock. This sale is related to a broker-assisted cashless exercise of employee stock options. The filing also details prior dispositions by David Rodman over several months in 2026.
MLYS: Lorundrostat advances toward FDA approval with strong clinical data and launch readiness
Mineralys Therapeutics' (MLYS) Lorundrostat is moving towards FDA approval, with its New Drug Application accepted in Q1 and strong clinical data supporting its use for resistant hypertension. The company is preparing for launch by engaging key prescribers and payers, while international commercialization will be handled through partnerships. Mineralys Therapeutics has sufficient cash reserves to fund operations until 2028.
[144] Mineralys Therapeutics, Inc. SEC Filing
Mineralys Therapeutics, Inc. filed a Form 144 notice for the proposed sale of 2,171 shares of common stock through a broker-assisted cashless exercise, effective May 11, 2026. The filing also documents multiple prior open-market dispositions by David Rodman between February and April 2026, including significant share blocks. Analysts consider the filing neutral, indicating routine liquidity events and required regulatory notice without immediate broader market impact unless volume is high relative to outstanding float.
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $52
Stifel has reiterated its Buy rating on Mineralys Therapeutics (MLYS.US) and maintained its price target of $52. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics (MLYS) announced its financial results for the first quarter of 2026, highlighting the FDA's acceptance of its New Drug Application (NDA) for lorundrostat, with a PDUFA target date of December 22, 2026. The company is actively engaged in pre-commercial activities for lorundrostat, an aldosterone synthase inhibitor for hypertension. Mineralys reported $646.1 million in cash, cash equivalents, and investments, projecting sufficiency to fund operations into 2028, and a net loss of $39.3 million for Q1 2026.
Mineralys Therapeutics Q1 2026 Earnings Call Transcript
Mineralys Therapeutics (MLYS) discussed its Q1 2026 earnings, highlighting the FDA's acceptance of the NDA for lorundrostat with a PDUFA target date of December 22, 2026. The company emphasized its strong clinical data showing significant blood pressure reductions and a favorable tolerability profile, supporting its potential launch focusing on the 4th-line/resistant hypertension population. Mineralys ended the quarter with $646.1 million in cash, sufficient to fund operations into 2028, despite increased G&A expenses for commercial readiness.
Earnings call transcript: Mineralys Therapeutics beats Q1 2026 EPS estimates
Mineralys Therapeutics (MLYS) announced a significant beat on its Q1 2026 EPS estimates, reporting -$0.47 against a forecast of -$0.81. The company also highlighted the NDA acceptance for its lead drug candidate, lorundrostat, for hypertension, with a PDUFA target date of December 22, 2026. Mineralys projects its $646.1 million cash reserves will fund operations into 2028 and is preparing for a potential U.S. market launch of lorundrostat by late 2026, while also exploring partnering opportunities.
FDA accepts Mineralys hypertension drug filing; Dec. 22 decision date
Mineralys Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for lorundrostat, a hypertension drug, setting a PDUFA target date of December 22, 2026. The company reported Q1 2026 financial results including $646.1 million in cash and investments, projected to fund operations into 2028, and a net loss of $39.3 million. Mineralys is now advancing pre-commercial activities for lorundrostat, which showed positive results across five clinical trials.
FDA accepts Mineralys (Nasdaq: MLYS) NDA for lorundrostat, sets Dec 2026 PDUFA
Mineralys Therapeutics announced that the FDA accepted its New Drug Application (NDA) for lorundrostat, a drug for hypertension, setting a PDUFA target date of December 22, 2026. The company also reported its Q1 2026 financial results, showing a net loss of $39.3 million, an improvement from the previous year, and confirmed that its cash reserves of $646.1 million are sufficient to fund operations into 2028. This acceptance marks a significant regulatory milestone, moving lorundrostat closer to potential commercialization.
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced its first quarter 2026 financial results, highlighted by the FDA's acceptance of their New Drug Application (NDA) for lorundrostat for hypertension, with a PDUFA target date of December 22, 2026. The company reported $646.1 million in cash, cash equivalents, and investments, believing this is sufficient to fund operations into 2028. They are also actively engaged in pre-commercial activities for lorundrostat.
Mineralys earnings in focus as resistant hypertension drug nears FDA decision
Mineralys Therapeutics Inc. is approaching a key FDA decision for its lead drug candidate, lorundrostat, for resistant hypertension. The company is expected to report a wider loss of $0.81 per share for the first quarter as it prepares for a potential commercial launch. Despite increasing losses, analysts maintain a bullish outlook with a "Strong Buy" consensus and a mean price target implying significant upside, focusing on the drug's blockbuster potential and competitive positioning against AstraZeneca's offering.
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) announced its participation in the Bank of America Securities 2026 Health Care Conference. Management will hold a fireside chat on May 12, 2026, at 9:20 am PT in Las Vegas, which will also be webcast live. The company focuses on developing medicines for hypertension and related comorbidities, with its lead product candidate being lorundrostat.
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics has announced it is issuing inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4). The specific details of these awards, which are a common practice for attracting and retaining talent, were not fully disclosed in the provided content. This report highlights the company's compliance with Nasdaq's listing rules regarding such incentives.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the granting of inducement stock option and restricted stock unit awards to two new non-executive employees on May 4, 2026. These awards, totaling 29,760 stock options and 22,320 restricted stock units, were granted under the company's 2025 Employment Inducement Incentive Award Plan. This action aligns with Nasdaq Listing Rule 5635(c)(4), as the awards are a material inducement for the new employees to join the company.
Two new Mineralys hires get stock options and RSUs under Nasdaq rule
Mineralys Therapeutics announced on May 5, 2026, the grant of inducement equity awards to two new non-executive employees. These awards include 29,760 stock options and 22,320 restricted stock units, vesting over four years with a first-year cliff. The grants were made under the 2025 Employment Inducement Incentive Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Mineralys to Report First-Quarter Results on May 6
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will announce its first-quarter financial results on Wednesday, May 6, after market close. The company will also hold a conference call at 4:30 p.m. Eastern Time to discuss the results, with details provided for both domestic and international participants, as well as a live webcast link. Mineralys focuses on developing therapies for hypertension and related conditions, with lorundrostat as its lead product candidate.
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Mineralys Therapeutics (NASDAQ: MLYS), a biopharmaceutical company specializing in treatments for hypertension and related conditions, announced its participation in the Bank of America Securities 2026 Health Care Conference. Management will engage in a fireside chat on May 12, 2026, which will also be accessible via live webcast. The company focuses on developing medicines like lorundrostat, an aldosterone synthase inhibitor, for diseases driven by dysregulated aldosterone.
Mineralys Therapeutics Advances Drug Commercialization Through Comprehensive Contract Support
Faegre Drinker Biddle & Reath LLP has been providing comprehensive contract support to Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company. This support includes reviewing, revising, negotiating, and finalizing a wide range of commercial contracts as Mineralys Therapeutics progresses its drug approval and commercialization efforts. The firm's team has assisted with over 100 contracts, collaborating with technology transactions and healthcare regulatory teams for specialized legal counsel.
Mineralys fireside chat at Bank of America conference streams May 12
Mineralys Therapeutics (NASDAQ: MLYS) announced its management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference in Las Vegas on May 12, 2026, at 9:20 a.m. PT. A live webcast of the session will be available on the company’s Investor Relations "News & Events" page. The company is expected to discuss its pipeline targeting hypertension and related comorbidities, including updates on lorundrostat and its NDA acceptance by the FDA.
(MLYS) Volatility Zones as Tactical Triggers
This article provides an analysis of Mineralys Therapeutics Inc. (NASDAQ: MLYS), highlighting neutral near and mid-term readings but maintaining a long-term positive bias. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry zones, targets, and stop losses. The analysis also details real-time signals, risk-reward setups, and multi-timeframe signal strengths to guide tactical trading decisions.
Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday
Mineralys Therapeutics (MLYS) is expected to release its Q1 2026 earnings after the market closes on Wednesday, May 6th, with analysts forecasting an EPS of ($0.51). The company previously beat estimates last quarter, reporting ($0.40) versus an expected ($0.57). Analysts currently have a "Moderate Buy" consensus rating for MLYS, with a target price of $49.14.
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Jennison Associates LLC
Jennison Associates LLC significantly increased its stake in Mineralys Therapeutics (MLYS) by 234.4% in Q4, acquiring over 1.25 million shares worth $45.7 million. This move contributes to institutional and hedge funds owning 84.46% of the company's stock, despite recent insider selling activity. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $49.14, following several recent "buy" ratings and price target boosts from firms like Bank of America and HC Wainwright.
Pictet Asset Management Holding SA Sells 76,286 Shares of Mineralys Therapeutics, Inc. $MLYS
Pictet Asset Management Holding SA reduced its stake in Mineralys Therapeutics (NASDAQ:MLYS) by 8.2% in the fourth quarter, selling 76,286 shares and retaining 852,883 shares valued at approximately $30.95 million. Insiders also sold 162,291 shares totaling about $4.34 million in the last quarter, though still owning 18.94% of the stock. Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $49.14, while the stock currently trades around $25.56.
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
Mineralys Therapeutics, a biopharmaceutical company specializing in treatments for hypertension and related conditions, announced that it will release its first-quarter 2026 financial results after the market closes on Wednesday, May 6, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. Interested parties can access the call via phone or through a live webcast on the company's investor relations website.
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's Why
Mineralys Therapeutics (NASDAQ:MLYS) shares gapped down by 2.2% on Wednesday, opening at $25.46 after closing at $26.99. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $49.14, despite some mixed coverage. Insider transactions show CEO Jon Congleton selling 75,000 shares, while Ra Capital Management acquired 310,700 shares.
Mineralys Therapeutics to Announce First Quarter 2026
Mineralys Therapeutics (Nasdaq: MLYS) announced it will report its first-quarter 2026 financial results after market close on Wednesday, May 6, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results. Mineralys Therapeutics is a biopharmaceutical company focused on developing therapies for hypertension and related conditions.
Mineralys Therapeutics to Announce First Quarter 2026
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced it will report its first quarter 2026 financial results after market close on Wednesday, May 6, 2026. The biopharmaceutical company, which focuses on hypertension and related comorbidities, will also host a conference call at 4:30 p.m. ET to discuss the results. Investors can access the call via phone or live webcast.
TD Cowen initiates coverage of Mineralys Therapeutics (MLYS) with buy recommendation
TD Cowen has initiated coverage of Mineralys Therapeutics (MLYS) with a buy recommendation. This positive outlook suggests that the investment firm sees potential for growth and good performance from the company's stock.
TD Cowen initiates coverage of Mineralys Therapeutics (MLYS) with buy recommendation
TD Cowen has initiated coverage of Mineralys Therapeutics (MLYS) with a buy recommendation. This positive outlook from the investment bank suggests confidence in the company's prospects. Investors will likely watch how MLYS stock performs following this new coverage.
Mineralys Therapeutics stock initiated at buy by TD Cowen on drug potential
TD Cowen initiated coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a buy rating, citing the "blockbuster potential" of its drug lorundrostat for hypertension, a market valued over $5 billion. The firm expects lorundrostat to split the market with AstraZeneca's baxdrostat and anticipates favorable pricing and access for Mineralys' drug. Despite a recent stock decline, analyst upgrades and strong Q4 2025 EPS support a bullish outlook, though concerns remain regarding increased G&A expenses and trial results.
Mineralys Therapeutics stock initiated at buy by TD Cowen on drug potential
TD Cowen initiated coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a buy rating, citing the "blockbuster potential" of its drug lorundrostat for uncontrolled and resistant hypertension, a market valued at over $5 billion annually. Despite an 8.5% decline in the past week, analysts expect lorundrostat to split the market evenly with AstraZeneca’s baxdrostat, potentially benefiting from a better label and favorable pricing. The firm also anticipates attractive merger and acquisition activity for Mineralys Therapeutics and noted recent upward earnings revisions by three analysts.
Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics Inc. (NASDAQ:MLYS) has appointed Jeffrey A. Munsie as its Chief Legal Officer. Munsie brings 25 years of biopharmaceutical experience to the role, where he will oversee legal and compliance functions, and provide strategic counsel for the company's lead candidate, lorundrostat. The company believes his background in all stages of drug development is crucial for its future growth, as Munsie helps advance treatments for dysregulated aldosterone.
Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics Inc. (NASDAQ: MLYS) has appointed Jeffrey A. Munsie as Chief Legal Officer, leveraging his 25 years of biopharmaceutical experience. Munsie will oversee legal and compliance functions, providing strategic counsel as the company advances its lead candidate, lorundrostat, for hypertension and related conditions. His background in drug development and intellectual property is expected to be crucial for the company's growth phase.
MLYS Price Today: Mineralys Therapeutics, Inc. Stock Price, Quote & Chart | MEXC
Mineralys Therapeutics, Inc. (MLYS) is currently trading at $27.49, reflecting a -3.55% change from its previous close, and has shown strong performance with a +102.69% price change over the last 12 months. The company is a biopharmaceutical firm developing lorundrostat for cardiorenal conditions, classified within the Pharmaceutical Preparations sector, and is listed on NASDAQ with a market capitalization of $2.27B. Investors can buy and trade MLYS on MEXC and track its financial performance through earnings reports.
